British technology increases cervical cancer detection by up to 24%

New peer reviewed research published by the European Journal of Obstetrics & Gynecology and Reproductive Biology shows that use of ZedScan in diagnostic screening significantly increased the detection of cancer and potential cancer.     

The biggest increase was in women referred with low grade changes, often the most challenging to visualise, where ZedScan had over a 50% increase in high grade disease detection.  

Scientists looked at the examinations of 5257 women by 82 colposcopists in 26 clinics in 9 different countries

Groundbreaking British technology increases cervical cancer detection by up to 24%

New peer reviewed research published by the European Journal of Obstetrics & Gynecology and Reproductive Biology shows that use of ZedScan in diagnostic screening significantly increased the detection of cancer and potential cancer.

The biggest increase was in women referred with low grade changes, often the most challenging to visualise, where ZedScan had over a 50 per cent increase in high grade disease detection.

UK innovation increases cervical cancer detection

New peer reviewed research published by the European Journal of Obstetrics & Gynecology and Reproductive Biology shows that use of ZedScan in diagnostic screening significantly increased the detection of cancer and potential cancer.

Results for all 26 centres showed the sensitivity of colposcopy using the CI method was 74.1% but increased to 91.6% with the use of ZedScan (p < 0.0001). Use of ZedScan increased the detection of high-grade CIN by 269 (24%) cases, a 7.5% increase in high grade cytology and 57.9% in low grade referrals.

11 Questions You’ve Always Wanted To Ask About Cervical Smear Tests

Zilico's Clinical Specialist Amanda Caley was happy to answer questions around cervial screening and colposopy to rasie awarness during Cerical Screening awarness week 2022.

Ever wished you could ask more questions about cervical screenings or smear tests, but worried you’ll sound silly?

The cervical screening programme helps save thousands of lives in the UK each year. But, it’s fair to say there’s still a fair bit of mystery about them, and they can be a bit awkward or nerve-wracking for some people.

GROUNDBREAKING BRITISH TECHNOLOGY INCREASES CERVICAL CANCER DETECTION BY UP TO 24%

20th June 2022 – New peer reviewed research published by the European Journal of Obstetrics & Gynecology and Reproductive Biology shows that use of ZedScan in diagnostic screening significantly increased the detection of cancer and potential cancer.

The biggest increase was in women referred with low grade changes, often the most challenging to visualise, where ZedScan had over a 50% increase in high grade disease detection.
Scientists looked at the examinations of 5257 women by 82 colposcopists in 26 clinics in 9 different countries. 

The full research can be viewed here and also showed that:

• HPV vaccination and primary HPV screening have been shown to be effective
• Women at low risk of high-grade CIN are now being referred to colposcopy
• In general colposcopy performs poorly when there is a low prevalence of high-grade CIN

Cervical Screening Awareness Week: 11 questions you’ve always wanted to ask about smear tests

Zilico's Clinical Specialist Amanda Caley was happy to answer questions around cervial screening and colposopy to rasie awarness during Cerical Screening awarness week 2022.

A Look at the Best Manchester-Based Investments in 2022

Clearly, Manchester is one of the leading cities for business and commerce in the UK, while it also places second on these shores for tech innovations.

...Zilico, this is a healthcare tech startup that’s focused on the development and production of early cancer diagnostics. This firm was founded in 2006 and continues to evolve having received more than £120,000 in innovation grants and £25.1 million worth of investment overall.

Novel ZedScan beneficial as adjunct to Colposcopy in the detection of cervical neoplasia: IJOGR

A study by Shalini Vasudeva and Ragini Thapa at the Department of Obstetrics & Gynaecology, Base Hospital, Delhi Cantt to evaluate and assess the accuracy of the detection of cervical intraepithelial neoplasia using electrical impedance spectroscopy with colposcopy.

Zilico secures Growth Private Equity investment from Deepbridge Capital

Zilico Ltd announces Further Investment and the Appointment of a new Chair of the Board of Directors

Early cancer diagnostic specialist, Zilico Ltd, has today announced further investment from existing investor, Deepbridge Capital and the appointment of Martin Frost CBE as its new Chairman.

New devices at BRI to help with cervical cancer diagnosis

Bradford Teaching Hospital’s Colposcopy Unit has received charity funding to introduce a device which will help to improve the diagnosis of cervical cancer in women referred to Bradford Royal Infirmary.

Oral cancer: Do you have symptoms? New technology could detect disease at an early stage

In partnership with Zilico Ltd, the University of Sheffield is developing a pain-free, non-invasive and instantaneous method to detect oral cancer.

The research collaboration has been awarded one million pounds in funding from SBRI Healthcare – an NHS England initiative.

Scientists to develop pain-free device to detect oral cancer

In partnership with Zilico Ltd, the University of Sheffield is working to develop a pain-free, non-invasive and instantaneous method to detect oral cancer.

VC firm invests £9m into North West growth companies

Chester-based, venture capital specialist, Deepbridge Capital has revealed that during the 2019/20 tax year it provided more than £9m of investment across 27 North West businesses.

New approach for immediate pain free diagnosis of oral cancers

Following Phase I funding awarded in March 2019, Zilico announced that they have been awarded Phase II funding as part of an initiative by SBRI Healthcare. It will help to identify innovations tackling healthcare problems in the area of dentistry, oral health and oral cancers.

Health board ‘really pleased’ to offer new clinic for women

CLINICS are now being held in Shetland with a specialist colposcopy nurse from Aberdeen which will potentially reduce the number of patients having to travel south.

The visiting nurse is using ZedScan, a diagnostic device that improves the detection and diagnosis of cervical cancer.

Zilico support access to vital cervical cancer screening and detection in remote areas

Manchester-based medical technology company Zilico Ltd are ensuring that women living in remote areas of the UK who need a colposcopic examination benefit from ZedScan™, a diagnostic device that improves the detection and diagnosis of cervical cancer.

Former Rangers star visits Dundee hospital to donate specialist cancer equipment

Ex-Rangers and Scotland winger Willie Henderson presented Ninewells staff with the ZedScan device on behalf of the Michelle Henderson Cervical Cancer Trust.

The ZedScan uses electrical impedance spectroscopy technology to detect abnormalities before they develop into cancer.

CEO Today CEO Today Europe Awards

CEO Today is pleased to announce that its 2019 Europe Awards edition has now been published. The CEO Today Europe Awards celebrate the success, innovation and strategic vision of CEOs in Europe, across a number of sectors and industries.

Cervical Cancer Diagnostic Market SWOT and Supply Chain Analysis 2019-2026 by Top Players

This report focuses on the global top players which are Guided Therapeutics, Beckman Coulter, Inc., QIAGEN, Arbor Vita Corporation, Becton, Dickinson and Company, Abbott Laboratories, Dell Guided Therapeutics, Inc., F. Hoffmann-La Roche Ltd, Zilico Ltd, Hologic, Inc., Quest Diagnostics, Inc, Cooper Surgical, Inc., Siemens, OncoHealth Corporation.

Excellence in Supply Awards 2019 - Shortlist Announced!

The finalists for the first NHS in the Midlands Excellence in Supply Awards have been announced and Zilico Ltd have been shortlisted for the Clinical Innovation Award.

Portable Cancer Screen Devices Market Will Reflect Significant Growth Prospects during 2018 – 2028

Incidence of cancer is rising rapidly in all the countries. Early detection increases the chances of survival. According to WHO, one in every 12 women has the risk of breast abnormality.  New methods and technologies are being developed for the early detection of cancer. The properties of the healthy cells vary when compared to the abnormal cancerous cells. Portable cancer screen devices detect the slight differences in the abnormal tissues. Unlike mammography used for detection of breast cancer the portable cancer screening device is radiation free, non-touch and does not pain. The portable cancer screening device is a boon for cancer diagnosis test in hospitals, can be used for regular preventive health check-ups, and also for large scale screening semi-urban and rural areas.

Winners of the 2019 HSJ Partnership Awards announced

The outstanding work that organisations are doing in partnership with the NHS was recognised with winners named in 16 categories at the 2019 HSJ Partnership Awards.

Zilico Ltd and Sheffield Teaching Hospitals Foundation Trust were the winners in the Medical Device or Hardware Innovation Award category.

Insightful Forecast on Expansion of Portable Cancer Screen Devices Market During 2018 – 2028

Incidence of cancer is rising rapidly in all the countries. Early detection increases the chances of survival.

Portable cancer screen devices market: Key Players – Some of the major players identified in portable cancer screen devices market. are  AdDent, Inc, Forward Science, LED Apteryx Inc., Breastlight, Zilico, Braster S.A, Bremed Ltd., TruScreen, Niramai among others.

SBRI Healthcare awards £1.25m to musculoskeletal disorder and oral health innovations

SBRI Healthcare has awarded £1.25 million to help fund the development of thirteen separate innovations relating to musculoskeletal disorder and dentistry, oral health and oral cancers. The pioneering projects were discovered through a nationwide call by SBRI Healthcare earlier this year for innovations to tackle healthcare problems in these fields.

Zilico have been awarded £99, 752 for the development of an oral pre-cancer/cancer in-vivo, real time diagnostic based on electrical characterisation of tissue.

Cervical Cancer Diagnostic Market 2025

Crystal Market Research has added the report on Cervical Cancer Diagnostic Market for the forecast till 2025, the report comprises of the estimation of the global Cervical Cancer Diagnostic Market.

Key players include Zilico Ltd.

Finalists for HSJ Partnership Awards 2019 revealed

The shortlist for the HSJ Partnership Awards 2019 has been announced today.

Zilico have been shortlisted in the Medical Device or Hardware category. The winners will be announced at the HSJ awards dinner on 20th March 2019.

Zilicos breaking new ground with a tool to diagnose cervical cancer

Watch the interview with CEO, Sameer Kothari as he talks to Proactive Investors about ZedScan.

Scottish football legend Willie Henderson provides life-saving machines for cervical cancer patients

A Scottish football legend who dedicated himself to cancer causes following the death of his daughter has helped provide funding for live saving devices at Aberdeen Royal Infirmary (ARI).

Willie Henderson was at the hospital on Monday to celebrate the arrival of two ZedScan machines, which use innovative technology to detect cell abnormalities in the cervix and drastically reduce the time taken to diagnose cervical cancer in women.

Med-Tech companies triumph at the Bionow Awards

The outstanding companies and leaders of the North’s life sciences sector – which is worth more than £13bn to the economy- were honoured last night at the 17th annual Bionow Awards. 

Blueberry Therapeutics, C4X Discovery, Zilico and LightOx all won prizes for the application of their cutting edge technologies to the life sciences sector.

Zilico appoint new head of quality assurance and regulatory affairs

Zilico, which develops products to help with cancer diagnoses, has appointed Kirsty Cook as its head of quality assurance and regulatory affairs.

Manchester based MedTech gains further adoption in Scotland following funding from Scottish Cervical Cancer charity

Zilico, a medical technology company, based at Manchester Science Park continues to see the adoption of ZedScan™ expand, as the Michelle Henderson Cervical Cancer Trust, funds the purchase of two ZedScan devices at Aberdeen Royal Infirmary’s colposcopy unit, to help prevent women developing cervical cancer.

Scotland star’s charity donates devices to help north-east cancer patients

A charity has funded new equipment which could benefit up to 2,500 cervical cancer patients in the north-east every year.

Football legend Willie Henderson donated two Zedscan diagnostic devices to the colonoscopy unit at Aberdeen Royal Infirmary (ARI) yesterday.

Zilico/ International Oncology Pilot

As an adjunct to colposcopy, Zedscan lends greater efficiency in detecting cervical cancer, ultimately saving lives and money. In their pilot in India with International Oncology, they aimed to increase early detection and quickly enable treatment.

Deepbridge puts £3m into Zilico

Zilico, part of the Deepbridge Technology Growth EIS portfolio, has secured investment of £13.7 million in its latest funding  round. 

Deepbridge has contributed £3 million of this, with other backers including MaxHealth Medicine Group.

Tech firm Zilico secures £13.5m investment to boost expansion

Tech firm Zilico has secured more than £13.5m in new investments to bolster its expansion plans.

The company, which is based at Manchester Science Park, has signed a strategic deal with the MaxHealth Medicine Group to allow it to sell ZedScan, the cervical cancer diagnostic system, to the Chinese market.

Zilico Raises $19M in Total Investments

Zilico, a Manchester, UK-based developer of a cervical cancer diagnostic system, raised a $19m in total funding.

The company will receive minimum royalties of $12m and investments totalling $7M.

Backers included the MaxHealth Medicine Group (stock code: 836163 (NEEQ) and Deepbridge Capital (UK).

ZedScan featured in the Mail on Sunday's Health supplement.

As a pilot site for primary HPV screening, Sheffield Teaching Hospital NHS Foundation Trust found that by using ZedScan™ as part of their routine colposcopy examination, clinicians were able to release high risk-HPV positive but cytology negative patients back to routine screening. 

Manchester diagnostics company raising awareness for gynaecological cancers

Zilico, who are based on the Manchester Science Park, is supporting The Eve Appeal’s UK campaign to help people become more aware of the early signs and symptoms.

The company is highlighting stories by clinicians, patients and their partners on social media throughout the month.

Cervical cancer diagnostic company welcomes new board member

Manchester Science Park based cervical cancer diagnostic specialist Zilico has today announced that it has appointed new member, Dr Savvas Neophytou to its Board of Directors. 

Cervical cancer diagnostic company announces operational changes

Cervical cancer diagnostic specialist Zilico, has today announced a number of operational changes designed to better align its operations.

Going forward, Zilico's flagship product ZedScan™, which improves the speed and accuracy in diagnosing pre-cancerous conditions of the cervix, will be sold directly to hospitals in Great Britain (Wales, Scotland & England) rather than through a third party distributor.

Medica '16 Thriving

The annual Medica exhibition in Dusseldorf, Germany- adjacent to the much smaller Copamed show- typically attracts the cream of UK producers of medical and healthcare products.

A pioneering diagnostic system that is having a significant impact on the changing clinical pathway for cervical cancer was exhibited at Medica 2016 by Zilico Ltd.

UK Cervical Cancer Diagnostic System Chosen for Pilot Study in India

UK cervical cancer diagnostic system to be piloted in India as part of TechEmerge's programme

Zilico Ltd- a developer of a pioneering cervical cancer diagnostic system- has been selected by the IFC, a member of the World Bank Group, to be part of a unique programme across India. (p6)

Manchester on the Move: The UK's Industrial Engine Room is Fast Becoming a Life Science Power House

Manchester, a city in the north of England, is a place that welcomes innovation. From the Museum of Science and Industry,  to its more than 20 libraries Manchester is a city as hungry for knowledge and progress now as it ever was.(pp8-12)

Over 250 participants took part in the XII th National Forum of health care professionals in Shumen

For the 12th time Grand hotel "Shumen" brought together health care professionals across the country.

National Forum this year is entitled "Continuous care - a condition for quality of life," and it involved over 250 participants, 37 of which presented their reports.

"The contribution of nurses and midwives to provide continuous care in outpatient conditions" - prof. Sonia Tontcheva, MD - Director of Subsidiary Shumen to Varna MU, National Consultant in Health Care;

" Colposcopy and ZedScan spectroscopy in the diagnosis of precancerous cervical "- Prof. Dr. Yavor Kornovski, MD - Head of the Department of Health Care to Shumen branch of MU-Varna;

"Maxillofacial Surgery in Bulgaria - known and unknown" - Prof. Dr. Tsvetan Tonchev, MD, Ph.D. - Dean of the Faculty of Dental Medicine at MU Varna.

Manchester company showcases pioneering diagnostic system on world healthcare stage

A pioneering diagnostic system that is having a significant impact on the changing clinical pathway for cervical cancer will be on display at MEDICA 2016 – the largest healthcare exhibition in the world - by Manchester based Zilico Ltd.

Pioneering diagnostic system to be showcased at MEDICA 2016

ZedScan will have a significant impact on the clinical pathway for cervical cancer
A pioneering diagnostic system that is having a significant impact on the changing clinical pathway for cervical cancer will be exhibited by Zilico in Hall 16, Stand F18-5 at MEDICA 2016, which takes place from 14–17 November in Duesseldorf.

Cervical Cancer Diagnostic System at MEDICA 2016

A frequent visitor to our pages, UK device company  Zilico Ltd., is showcasing its pioneering cervical cancer diagnostic technology at this year’s Medica 2016.

Cervical cancer: New scanners help fight against disease in the Midlands

The University Hospitals of North Midlands NHS Trust has adopted the diagnostic system, called ZedScan, at the gynaecology departments at both the Royal Stoke University Hospital and the County Hospital.

HSJ awards 2016 shortlist revealed

The shortlisted organisations will now complete presentations and interviews to a specific judging panel made up of senior and influential figures from the health sector. The winners will be announced at a prestigious ceremony on 23 November at the InterContinental O2, London.

Zilico Shortlisted for Prestigious Healthcare Award

Manchester based Zilico has been shortlisted in the ‘Improving Care with Technology’ category at the 2016 Health Service Journal (HSJ) Awards, to be held on 23 November at Intercontinental O2, London

Manchester firm's pioneering technology for cervical cancer diagnosis

PIONEERING technology created by a Manchester company is now being used in two hospitals in Staffordshire to improve the speed and accuracy in diagnosing pre-cancerous conditions of the cervix.

Pioneering Technology Created By Manchester Company Used In Staffordshire To Offer More Accurate Cervical Cancer Diagnosis

Pioneering technology created by a Manchester company is now being used in two hospitals in Staffordshire to improve the speed and accuracy in diagnosing pre-cancerous conditions of the cervix.

Real Time Smear Test Offering More Accurate Cervical Cancer Diagnosis in UK Hospitals

ZedScan Portable Cervical Smear System adopted in two more UK hospitals

Staffordshire Hospitals offer more accurate cervical cancer diagnosis

The University Hospitals of North Midlands NHS Trust have adopted an innovative cervical cancer diagnostic system called ZedScan at the gynaecology departments at both the Royal Stoke University Hospital and County Hospital Stafford. Its aim is to offer a more accurate diagnosis for women who are at risk of cervical cancer.

Women could get faster cervical cancer diagnosis at Stafford's County Hospital

Women could get faster and more accurate diagnoses of pre-cancerous conditions of the cervix now Stafford's County Hospital has introduced a pioneering new technology.

ZedScan is a portable, handheld device which can measure and detect tissue changes in women identified with an abnormal smear test.

ZedScan delivers high rates of HG CIN detection in hrHPV positive women

A review into the management of more than 800 women referred to an NHS colposcopy clinic who were positive for high risk HPV (hrHPV) has revealed a substantial increase in detection of high grade cervical intraepithelial neoplasia (HG CIN) following the adoption of ZedScan into routine use.

A Long Adoption Trail

Zilico features in the SuperNorth Supplement of The Times discussing the support provided by the Academic Health Science Networks (AHSNs) to assist northern-based SMEs operating in the Life Sciences sector. (see page 7 of 12)

Conquering the Challenges of Colposcopy

A device that uses electrical impedance spectra to characterize abnormal cervical tissue may improve on the subjective nature of colposcopy and reduce the rate of cervical biopsy.

1000 patient case study published for ZedScan

Zilico has published a 1,000-patient case study for its cervical cancer diagnostic system, ZedScan, to coincide with the start of Cervical Cancer Prevention Week this week.

The patient review into the routine use of ZedScan as an adjunct to colposcopy has revealed that the technology significantly increases the rate of detection of high-grade cervical intraepithelial neoplasia (HG CIN).

UK company touts study of its cancer diagnostic

U.K. company Zilico has published a case study of its diagnostic for high-grade cervical intraepithelial neoplasia, dubbed ZedScan. Use of the technology improved the detection rate of the cancer by 12.4%, the company says. It uses electrical impedance spectroscopy to differentiate between normal, precancerous and cancerous tissues.

Zilico bolsters team with new commercial director

Andrew Saipe, who has 25 years’ experience in medical sales, joins Zilico from Purple Surgical, where he looked after many of the International markets for eight years.

NICE publishes Medtech Innovation Briefing on ZedScan

NICE has developed a Medtech Innovation Briefing outlining the benefits of using Zilico’s cervical cancer diagnostic system, ZedScan. These include lower biopsy rates, a reduction in overtreatment and adverse events, and a cost saving from the reduction in follow-up appointments

NICE publishes Medtech Innovation Briefing on ZedScan

The National Institute for Health and Care Excellence (NICE) has developed a Medtech Innovation Briefing (MIB) on Zilico Ltd’s cervical cancer diagnostic system, ZedScan.

NICE first developed the briefings in 2013 to help boost and speed-up the uptake of innovative and promising technologies which have the potential to improve patient health and increase NHS productivity.

ZedScan featured on BBC

BBC Business and Money Correspondent, Danni Hewson, interviews Prof. John Tidy from Sheffield Teaching Hospitals Foundation Trust (STH) along with a patient who underwent a ZedScan examination, after referral to coloposcopy following  an abnormal smear test. 

Sameer Kothari, Zilico's Chief Executive also discusses how ZedScan can have a global impact on patient care.

Sheffield leads the way for cervical cancer diagnosis

Patients at Sheffield Teaching Hospitals are to benefit from the introduction of a pioneering new system that improves the detection of precancerous abnormalities of the cervix.

The trust has become the first in the country to introduce the Zedscan device, which can measure and detect tissue changes in women identified with an abnormal smear test.

High-tech device

Women in Yorkshire will be the first in the country to benefit from a pioneering approach devised by experts in the region to improve the detection of the early signs of a common cancer.

Hospital staff in Sheffield have successfully tested a device which can measure and detect tissue changes in women with an abnormal smear test.

It offers more accurate detection of pre-cancerous abnormalities of the cervix than standard examinations, allowing doctors to make better informed decisions on a patient’s first visit.

Experts say it means appropriate treatment can be started quickly, or patients can be swiftly reassured if analysis shows nothing of concern. It also reduces unnecessary tissue biopsies.

First NHS trust to adopt ZedScan as part of cervical cancer care pathway

DP Medical Ltd has secured a deal with Sheffield Teaching Hospitals NHS Foundation Trust (STHFT) to become the first NHS Trust in the country to adopt ZedScan™ as part of its cervical cancer care pathway.

The ground-breaking system, which includes its patented Electrical Impedance Spectroscopy technology, offers quicker and more accurate detection of cervical neoplasia delivering results in real-time, enabling clinicians to improve patient management.

Zilico Success in Australia

Triteq have worked with Zilico Ltd,  a spin-out company from Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield, from the initial concept stage of Zedscan 1, a ground breaking cervical cancer diagnostic device.  So we were  delighted to hear that ZedScan I has obtained approval from Therapeutic Goods Administration (TGA) in Australia.

Relocating a small business: the pros, cons and necessary preparations

Manchester has also been a destination for some relocating companies, including medical sciences business Zilico which moved across the Pennines from Sheffield in late 2012.

At the time the company had just finished a multi-centre trial, was looking for a bigger hub and wanted to be based closer to an international airport, said Zilico's chief executive Sameer Kothari.

The move to Manchester Science Park helped Zilico access private equity finance and support from north-west-based NHS trusts. "I can't say it was specifically because we were based in Manchester, but it did help," says Kothari.

Real-time cervical cancer diagnostics: An interview with Sameer Kothari, Chief Executive of Zilico

Sameer Kothari outlines the current limitations of the diagnostic process for cervical cancer and discusses how the development of ZedScan, Zilico's cervical cancer diagnostic system, will improve diagnostic accuracy.

Doctor, our start-ups need a cash injection

Medical tech companies need constant care if they are to survive and grow

Bruce Hellman swiped his finger over his iPad screen. “This is how patients are reminded to take their medication,” he said, “and they can choose a brain training exercise.”

Zilico receives EC Certification for ZedScan

ZILICO has received EC certification from its Notified Body for the ZedScan cervical cancer diagnostics device, which is said to offer faster and more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management.

The ZedScan system is used alongside colposcopy on women identified with an abnormal smear result. It can offer clinical benefits by identifying the optimum biopsy site, reducing the number of cervical biopsies required while also facilitating a wider use of ‘select & treat’.

The system, which is both safe and painless, consists of a portable hand-held device and docking station, software application and a single-use EIS sensor. Five clinical trials in the UK and EU have supported the clinical efficacy of ZedScan, including a pivotal European trial of 429 women in 2011 across three hospitals in the UK and Ireland.

Zilico Ltd cervical cancer diagnostics tool

Zilico Ltd will present its pioneering cervical cancer diagnostics tool at Medica 2012 - the world’s premier healthcare exhibition.